Category Archives: Global News Feed

Fourth Quarter 2022 Net Revenue Increased 33% from Third Quarter 2022 While GAAP Quarter-Over-Quarter OPEX Decreased 55% and Non-GAAP OPEX Remained Unchanged

Read the original:
Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update

SAN DIEGO and SUZHOU, China and SHANGHAI, China, March 22, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in two upcoming investor conferences.

Read the original post:
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2022.

More here:
Infant Bacterial Therapeutics publishes Annual Report for 2022

WALTHAM, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the publication of research in the peer-reviewed journal Science Translational Medicine describing a model for evaluating biomarker correlates of protection for monoclonal antibodies (mAb) against symptomatic COVID-19. The research concluded that neutralizing antibodies are mechanistic in providing protection against symptomatic disease and identified serum neutralizing antibody titers as a correlate of protection. These findings have potential to support accelerated development and innovative regulatory frameworks for mAbs for prevention of COVID-19.

Read more:
Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19

ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022

See the original post here:
ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022

CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced corporate updates including advances in its zagociguat (formerly CY6463) mitochondrial disease program.

See the rest here:
Cyclerion Reports Corporate Update and Full Year 2022 Financial Results